Evidence map›Paper›PMID 16842866›Full record

ArticleAntiviral research2007

Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.

Yan-Jin Zhang, Kai-Yu Wang, David A Stein, Deendayal Patel, Rheba Watkins, Hong M Moulton, Patrick L Iversen, David O Matson

Open access · hybridAbstract read
In one paragraph

Article in Antiviral research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Inhibition of Asthma in OVA Sensitized Mice Model by a Traditional Uygur Herb Nepeta bracteata Benth.Evidence-based complementary and alternative medicine : eCAM · 2016
    Article
  16. Kaposi's Sarcoma Herpesvirus Genome Persistence.Frontiers in microbiology · 2016
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yan-Jin ZhangCenter for Pediatric Research, Eastern Virginia Medical School, Norfolk, VA 23510, USA. zhangyj@umd.edu
Kai-Yu Wang
David A Stein
Deendayal Patel
Rheba Watkins
Hong M Moulton
Patrick L Iversen
David O Matson
Eastern Virginia Medical School · USSarepta Therapeutics (United States) · USUniversity of Maryland, College Park · US

Funding

Morpholino Antisense Drugs for Human Herpesvirus 8R21CA103612 · NCI · UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS · PI ZHANG, YAN-JIN · 2004 to 2005
$383k
NCI NIH HHS CA-103612NCI NIH HHS R21 CA103612
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with Kaposi's sarcoma and primary effusion lymphoma (PEL). The KSHV replication and transcription activator (RTA) and latency-associated nuclear antigen (LANA) play key roles in activating KSHV lytic replication and maintaining KSHV latency, respectively. Phosphorodiamidate morpholino oligomers (PMO) are similar to short single-stranded DNA oligomers, but possess a modified backbone that confers highly specific binding and resistance to nucleases. In this study, RTA and LANA mRNA in PEL cells were targeted by antisense peptide-conjugated PMO (P-PMO) in an effort to suppress KSHV replication. Highly efficient P-PMO uptake by PEL cells was observed. Treatment of PEL cells with a RTA P-PMO (RP1) reduced RTA expression in a dose-dependent and sequence-specific manner, and also caused a significant decrease in several KSHV early and late gene products, including vIL-6, vIRF-1, and ORF-K8.1A. KSHV viral DNA levels were reduced both in cells and culture supernatants of RP1 P-PMO-treated cells, indicating that KSHV lytic replication was suppressed. Treatment of BCBL-1 cells with P-PMO against LANA resulted in a reduction of LANA expression. Cell viability assays detected no cytotoxicity from P-PMO alone, within the concentration range used for the experiments in this study. These results suggest that RP1 P-PMO can specifically block KSHV replication, and further study is warranted.

Indexed as

Antigens, ViralBase SequenceCell Line, TumorDNA ReplicationGene Expression Regulation, ViralHerpesvirus 8, HumanHumansImmediate-Early ProteinsMolecular Sequence DataMorpholinesMorpholinosNuclear ProteinsTrans-ActivatorsViral ProteinsVirus LatencyVirus ReplicationAntigens, ViralImmediate-Early Proteinslatency-associated nuclear antigenMorpholinesMorpholinosNuclear ProteinsRta protein, Human herpesvirus 8Trans-ActivatorsViral Proteins

Identifiers

PMID16842866
PMCPMC2390898
OpenAlexW2034384002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.